Cargando…

Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer

Ubiquitin and ubiquitin-related proteins posttranslationally modify substrates, and thereby alter the functions of their targets. The ubiquitination process is involved in various physiological responses, and dysregulation of components of the ubiquitin system has been linked to many diseases includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Masoumi, K. C., Shaw-Hallgren, Gina, Massoumi, Ramin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246786/
https://www.ncbi.nlm.nih.gov/pubmed/22235375
http://dx.doi.org/10.1155/2011/614097
_version_ 1782219990972235776
author Masoumi, K. C.
Shaw-Hallgren, Gina
Massoumi, Ramin
author_facet Masoumi, K. C.
Shaw-Hallgren, Gina
Massoumi, Ramin
author_sort Masoumi, K. C.
collection PubMed
description Ubiquitin and ubiquitin-related proteins posttranslationally modify substrates, and thereby alter the functions of their targets. The ubiquitination process is involved in various physiological responses, and dysregulation of components of the ubiquitin system has been linked to many diseases including skin cancer. The ubiquitin pathways activated among skin cancers are highly diverse and may reflect the various characteristics of the cancer type. Basal cell carcinoma and squamous cell carcinoma, the most common types of human skin cancer, are instances where the involvement of the deubiquitination enzyme CYLD has been recently highlighted. In basal cell carcinoma, the tumor suppressor protein CYLD is repressed at the transcriptional levels through hedgehog signaling pathway. Downregulation of CYLD in basal cell carcinoma was also shown to interfere with TrkC expression and signaling, thereby promoting cancer progression. By contrast, the level of CYLD is unchanged in squamous cell carcinoma, instead, catalytic inactivation of CYLD in the skin has been linked to the development of squamous cell carcinoma. This paper will focus on the current knowledge that links CYLD to nonmelanoma skin cancers and will explore recent insights regarding CYLD regulation of NF-κB and hedgehog signaling during the development and progression of these types of human tumors.
format Online
Article
Text
id pubmed-3246786
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32467862012-01-10 Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer Masoumi, K. C. Shaw-Hallgren, Gina Massoumi, Ramin J Skin Cancer Review Article Ubiquitin and ubiquitin-related proteins posttranslationally modify substrates, and thereby alter the functions of their targets. The ubiquitination process is involved in various physiological responses, and dysregulation of components of the ubiquitin system has been linked to many diseases including skin cancer. The ubiquitin pathways activated among skin cancers are highly diverse and may reflect the various characteristics of the cancer type. Basal cell carcinoma and squamous cell carcinoma, the most common types of human skin cancer, are instances where the involvement of the deubiquitination enzyme CYLD has been recently highlighted. In basal cell carcinoma, the tumor suppressor protein CYLD is repressed at the transcriptional levels through hedgehog signaling pathway. Downregulation of CYLD in basal cell carcinoma was also shown to interfere with TrkC expression and signaling, thereby promoting cancer progression. By contrast, the level of CYLD is unchanged in squamous cell carcinoma, instead, catalytic inactivation of CYLD in the skin has been linked to the development of squamous cell carcinoma. This paper will focus on the current knowledge that links CYLD to nonmelanoma skin cancers and will explore recent insights regarding CYLD regulation of NF-κB and hedgehog signaling during the development and progression of these types of human tumors. Hindawi Publishing Corporation 2011 2011-12-17 /pmc/articles/PMC3246786/ /pubmed/22235375 http://dx.doi.org/10.1155/2011/614097 Text en Copyright © 2011 K. C. Masoumi et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Masoumi, K. C.
Shaw-Hallgren, Gina
Massoumi, Ramin
Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer
title Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer
title_full Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer
title_fullStr Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer
title_full_unstemmed Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer
title_short Tumor Suppressor Function of CYLD in Nonmelanoma Skin Cancer
title_sort tumor suppressor function of cyld in nonmelanoma skin cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246786/
https://www.ncbi.nlm.nih.gov/pubmed/22235375
http://dx.doi.org/10.1155/2011/614097
work_keys_str_mv AT masoumikc tumorsuppressorfunctionofcyldinnonmelanomaskincancer
AT shawhallgrengina tumorsuppressorfunctionofcyldinnonmelanomaskincancer
AT massoumiramin tumorsuppressorfunctionofcyldinnonmelanomaskincancer